Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study

Ophthalmology

Volumn 120, Issue 9, 2013, Pages 1893-1900

  Jackson, Timothy L ^a   Chakravarthy, Usha ^b   Kaiser, Peter K ^c   Slakter, Jason S ^d   Jan, Ernest ^e   Bandello, Francesco ^f   O'Shaughnessy, Denis ^g   Gertner, Michael E ^h   Danielson, Linda ⁱ   Moshfeghi, Darius M ^j  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Digital Angiography Reading Center   (United States)

^e CENTRAL MILITARY HOSPITAL   (Czech Republic)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g Oraya Therapeutics Inc   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXUDATIVE MACULAR DEGENERATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHOTOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; STEREOTACTIC TREATMENT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; RADIOSURGERY; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84883761161     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.02.016     Document Type: Article

References (36)

1. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N Engl J Med 358 2008 2606 2617
2. U. Chakravarthy, J. Evans, and P.J. Rosenfeld Age related macular degeneration BMJ 340 2010 c981
3. H.R. Coleman, C.C. Chan, F.L. Ferris III, and E.Y. Chew Age-related macular degeneration Lancet 372 2008 1835 1845
4. F. Rodel, L. Keilholz, and M. Herrmann Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy Int J Radiat Biol 83 2007 357 366
5. C. Hadjimichael, D. Kardamakis, and S. Papaioannou Irradiation dose-response effects on angiogenesis and involvement of nitric oxide Anticancer Res 25 2005 1059 1065
6. O. Hatjikondi, P. Ravazoula, and D. Kardamakis In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity Br J Cancer 74 1996 1916 1923
7. J.F. Kirwan, P.H. Constable, I.E. Murdoch, and P.T. Khaw Beta irradiation: new uses for an old treatment: a review Eye (Lond) 17 2003 207 215
8. U. Chakravarthy, R.F. Houston, and D.B. Archer Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study Br J Ophthalmol 77 1993 265 273
9. J.R. Evans, V. Sivagnanavel, and V. Chong Radiotherapy for neovascular age-related macular degeneration Cochrane Database Syst Rev 5 2010 CD004004
10. R. Petrarca, and T.L. Jackson Radiation therapy for neovascular age-related macular degeneration Clin Ophthalmol 5 2011 57 63
11. R. Petrarca, M. Richardson, and J. Nau Safety testing of epimacular brachytherapy with microperimetry and indocyanine green angiography: 12 month results Retina 33 2013 1232 1240
12. P.U. Dugel, R. Petrarca, and M. Bennett Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results Ophthalmology 119 2012 1425 1431
13. M.P. Avila, M.E. Farah, and A. Santos Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration Retina 32 2012 10 18
14. P.U. Dugel, J.D. Bebchuk, J. Nau CABERNET Study Group Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET) Ophthalmology 120 2013 317 327
15. A.A. Moshfeghi, V.M. Canton, and H. Quiroz-Mercado 16-Gy low-voltage X-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy Ophthalmic Surg Lasers Imaging 42 2011 460 467
16. M.R. Barakat, M. Shusterman, and D. Moshfeghi Pilot study of the delivery of microcollimated pars plana external beam radiation in porcine eyes Arch Ophthalmol 129 2011 628 632
17. M. Gertner, E. Chell, and K.H. Pan Stereotactic targeting and dose verification for age-related macular degeneration Med Phys 37 2010 600 606
18. J. Hanlon, M. Firpo, and E. Chell Stereotactic radiosurgery for AMD: a Monte Carlo-based assessment of patient-specific tissue doses Invest Ophthalmol Vis Sci 52 2011 2334 2342
19. J. Hanlon, C. Lee, and E. Chell Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose Med Phys 36 2009 3671 3681
20. C. Lee, E. Chell, and M. Gertner Dosimetry characterization of a multibeam radiotherapy treatment for age-related macular degeneration Med Phys 35 2008 5151 5160
21. P.J. Taddei, E. Chell, and S. Hansen Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration Phys Med Biol 55 2010 7037 7054
22. V.M. Canton, H. Quiroz-Mercado, and R. Velez-Montoya 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes Ophthalmic Surg Lasers Imaging 42 2011 468 473
23. V.M. Canton, H. Quiroz-Mercado, and R. Velez-Montoya 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes Ophthalmic Surg Lasers Imaging 43 2012 20 24
24. A.A. Moshfeghi, V. Morales-Canton, and H. Quiroz-Mercado 16-Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy Br J Ophthlamol 96 2012 1320 1324
25. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
26. C.H. Mallinckrod, P.W. Lane, and D. Schnell Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials Drug Inf J 42 2008 303 319
27. Peregrine Pharmaceuticals licenses anti-VEGF antibodies to Affitech [press release] July 22, 2009 Peregrine Pharmaceuticals Inc Tustin, CA http://ir.peregrineinc.com/releasedetail.cfm?releaseid=398241 Accessed June 7, 2012
28. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
29. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
30. G.A. Lalwani, P.J. Rosenfeld, and A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58
31. M. Larsen, U. Schmidt-Erfurth, P. Lanzetta MONT BLANC Study Group Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC Study results Ophthalmology 119 2012 992 1000
32. F.G. Holz, W. Amoaku, J. Donate SUSTAIN Study Group Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study Ophthalmology 118 2011 663 671
33. IVAN Study Investigators U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
34. L.H. Curtis, B.G. Hammill, and L.G. Qualls Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries Am J Ophthalmol 152 2012 1116 1124
35. M.P. Avila, M.E. Farah, and A. Santos Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration Br J Ophthalmol 93 2009 305 309
36. P.M. Beer, S.J. Bakri, and R.J. Singh Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection Ophthalmology 110 2003 681 686